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ABSTRACT
Background: Tumor associated macrophages (TAMs) have multifaceted roles 
in the development of many tumor types. However, the prognostic value of TAMs in 
bladder cancer is still not conclusive.
Experimental design: This review evaluated the prognostic value of TAMs density in 
bladder cancer by reviewing published literatures and integrating the results via a meta-
analysis. A systematic search was conducted in PubMed, Embase and Chinese National 
Knowledge Infrastructure (CNKI), WanFang, and Web of Science databases for relevant 
studies. Overall survival (OS), relapse free survival (RFS), disease specific survival (DSS), 
and progression free survival (PFS) were assessed in bladder cancer patients.
Results: The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) 
indicated that TAMs identified with CD68 alone have no significant correlation with 
OS (HR = 1.01, 95% CI = 1.00–1.02), RFS (HR = 0.99, 95% CI = 0.91–1.06), or PFS 
(HR = 1.19, 95% CI = 0.70–1.68) in bladder cancer patients. Subgroup analyses 
involved with Bacillus Calmette Guerin (BCG) treatment or sample locations either 
showed that CD68+ TAMs presented no prognostic value with regard to OS in bladder 
cancer patients. However, TAMs detected by CD163 are significantly correlated with 
poor RFS in bladder cancer patients (HR = 1.54, 95% CI = 1.16–1.92).
Conclusions: Our data indicated that TAMs identified only with CD68 have 
no significant correlation with the prognosis and clinicopathological parameters 
of bladder cancer patients. However, TAMs detected with CD163 could serve as a 
prognostic marker for bladder cancer patients. These findings invite further research 
on the role of TAM subsets in bladder cancer patients.
INTRODUCTION
Bladder cancer is one of the most common 
malignant tumors in urological diseases. In USA alone, 
58950 new cases of bladder cancer and 11820 cases 
bladder cancer related deaths were estimated in 2016. 
These accounted for 7% of all new cancer diagnoses and 
4% of all cancer deaths [1]. Transurethral resection of 
bladder tumor (TURBT) or radical cystectomy (RC) is 
the primary therapy for NMIBC or MIBC respectively. 
Following TURBT, bladder instillation of drugs was taken 
as effective choice to prevent or reduce the recurrence, 
especially for intermediate and high risk bladder tumors. 
Many kinds of drugs were recommended to be in use 
after TURBT, such as chemotherapy and immunotherapy 
drugs [2]. Bacillus Calmette-Guerin (BCG) intravesical 
immunotherapy is a classic and effective therapy to inhibit 
the relapse of intermediate and high risk non-muscle-
invasive bladder cancer (NMIBC). However, around 39% 
of NMIBC patients still relapse and 8% will progress 
to muscle-invasive bladder cancer (MIBC) [3–5]. High 
recurrence rate of NMIBC results in repeated TURBT, 
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which leads to huge physical and economical burden to 
the patients. Hence, it is critical to explore and validate 
new prognostic biomarkers, which may be helpful for the 
treatment decisions and the management of bladder cancer.
Macrophages are important regulators in both 
tissues homeostasis and tumor progression. Increasing 
evidences have shown that tumor associated macrophages 
(TAMs) are involved in tumor initiation, progression, 
angiogenesis, drugs resistance and metastasis. Different 
phenotypes of macrophages often present different roles 
in tumor microenvironment, which are tightly regulated 
by factors in the tumor microenvironment including 
interleukin-4, interleukin-10, immunoglobulin etc. [6]. 
Several recent studies have investigated the 
prognostic role of TAMs in different tumors [7, 8]. In 
many cancer types (such as gastric cancer, breast cancer, 
thyroid cancer), high density of TAMs is correlated 
with poor prognosis. However, in colorectal cancer high 
density of TAMs is correlated with good prognosis [7–9]. 
Moreover, the prognostic role of TAMs in specific cancer 
type may vary depending on different biomarkers used for 
TAM detection or quantification in various parts of the 
samples [8, 9]. As for bladder cancer, the prognostic role 
of TAMs in bladder cancer remains controversial among 
different studies [10–22]. To address this controversy, 
we performed this meta-analysis based on the TAMs 
identified by CD68 and CD163 markers to evaluate 
the potential association between TAMs density and 
prognostic outcomes in bladder cancer.
RESULTS
Search results and characteristics of studies
1238 records were identified from the different 
databases with keywords and search strategy detailed 
in methods. 418 duplicate records were removed by the 
detection of Endnote X7 software. The remaining records 
were screened by the titles and abstracts, and 220 records 
were excluded for case reports, reviews, letters, comments 
or meeting abstract. 600 remaining studies were further 
evaluated for eligibility, and 587 studies were further 
excluded for the following reasons: animal studies, not 
relevant with prognosis of TAMs identified with IHC 
in bladder cancer patients, without sufficient data to 
extract the HRs and 95% CIs. Based on the inclusion and 
exclusion criteria detailed in methods, 13 studies with 
macrophages detected by immunohistochemistry (IHC) in 
tumor samples were included for meta-analysis [10–22]. 
The flow chart of search strategy was shown in Figure 1.
12 of 13 included studies were published in English, 
while 1 study was published in Chinese. The total sample 
size for all records was 1400 cases (range from 27 to 
337). Among these cases, 294 of them underwent BCG 
treatment. Of the 13 studies, 8 studies detected TAMs in 
whole sample area (or not specified) [10, 13–17, 21, 22], 
2 studies were involved with TAMs detected in tumor islet 
and tumor stroma, respectively [19, 20], 1 study focused 
TAMs locating in tumor stroma [18], 1 study reported 
TAMs detected in tumor islet, tumor stroma and whole 
sample area, respectively [12], and 1study investigated 
macrophages identified in invasive front or middle to 
superficial carcinoma parts separately [11]. OS, RFS, 
DSS and PFS were used jointly or separately as prognostic 
endpoints in the included studies. Details were depicted 
in Table 1 and the mean Newcastle-Ottawa Scale (NOS) 
scores of publication quality were 7.54.
Detection of tumor associated macrophages
CD68 was used for identification of TAMs in 12 of 
the 13 included studies, including 2 studies in combination 
with CD163 [15, 22]. Both CD68 and CD163 biomarkers 
were identified by immunohistochemical staining in all the 
included studies. The antibodies are listed in Table 1. The 
prognostic role of CD68+ TAMs on RFS was assessed in 
7 studies [12–16, 21, 22], of which 2 studies calculated 
CD68+ TAMs in different locations [12, 19]. The 
prognostic role of CD68+ TAMs on DSS was assessed in 
3 studies, of which 1 study investigated the correlation of 
TAMs with DSS in two populations of patients treated by 
TUR or RC, and Koga F’s study analyzed the association 
between DSS and TAMs identified in different locations 
[11, 17, 21]. The prognostic role of CD68+ TAMs on OS 
was evaluated in 3 studies, of which 1 study evaluated 
the relationship between CD68+ TAMs and OS in TUR or 
RC population, respectively [10, 19, 21]. Moreover, the 
prognostic role of CD68+ TAMs on PFS was assessed in 
2 studies [17, 21]. The prognostic role of TAMs identified 
with CD163 on RFS was evaluated in 4 studies, of which 1 
study assessed the correlation of RFS with CD163 detected 
in tumor stroma or islet, respectively [15, 18, 20, 22].
The association between CD68+ TAMs and 
prognostic outcomes 
Although Hanada T, et al [10] reported that higher 
CD68+ TAMs density significantly correlated with 
decreased OS (HR = 5.0, 95% CI = 1.98 ~ 12.64), the 
pooled HR concerning the prognostic role of CD68+ TAMs 
on OS was 1.01 (95% CI = 1.00 ~ 1.02) (Figure 2A), 
which indicated the prognostic role of CD68+ TAMs 
should be cautiously interpreted in bladder cancer patients. 
As for the prognostic value of CD68+ TAMs 
on RFS, the pooled HR showed that elevated CD68+ 
TAMs density was not significantly associated with 
the RFS (HR = 0.99, 95% CI = 0.91 ~ 1.06) (Figure 
3, Overall). Furthermore, subgroup analyses according 
to the CD68+ TAMs in different sample locations 
also showed that the high CD68+ TAMs infiltration 
presented no significant correlation with RFS in bladder 
cancer patients with regard to whole sample area (or 
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not specified) (HR = 1.06, 95% CI = 0.58 ~ 1.53) 
(Figure 3, Location=whole), tumor stroma (HR = 1.00, 
95% CI = 0.91 ~ 1.10) (Figure 3, Location=stroma) 
and tumor islet (HR = 1.00, 95% CI = 0.97 ~ 1.02) 
(Figure 3, Location=intratumor). Similarly, subgroup 
analyses according to the history of BCG treatment 
showed that the pooled HRs for RFS in the patients 
with or without BCG therapy were 0.96 (95% CI = 0.79 
~ 1.14) and 0.99 (95% CI = 0.97 ~ 1.02), respectively 
(Supplementary Figure 1). Collectively, no significant 
correlation between CD68+ TAMs and RFS could be 
found in bladder cancer patients.
To further investigate the prognostic role of 
CD68+ TAMs on DSS, the pooled HRs demonstrated no 
significant association between CD68+ TAMs and DSS 
in bladder cancer patients (HR = 1.01, 95% CI = 1.00 ~ 
1.02) (Figure 2B). Moreover, the pooled results based on 
meta-analysis also indicated that there was no significant 
association between CD68+ TAMs and PFS in bladder 
cancer patients (HR = 1.19, 95% CI = 0.70~1.68) (Figure 
2C). Taken together, no significant association could be 
found between CD68+ TAMs and OS, RFS, DSS and PFS 
of bladder cancer patients in our meta-analysis.
The association of CD68+ TAM with 
clinicopathological characteristics 
We further evaluated the role of elevated TAMs 
with the clinicopathological parameters in bladder 
cancer patients. Four of the 13 included studies have 
presented relevant data of the association between 
clinicopathological parameters and CD68+ TAMs, while 
there was not enough data for CD163+ TAMs. Pooled 
analysis showed no significant correlation between elevated 
CD68+ TAMs infiltration and sex (Male vs. Female), sge 
(≥ 70 years VS < 70 years), carcinoma in situ (yes vs. no), 
tumor stage (T1 vs. Ta), tumor grade (≥ 2 vs. 1) or tumor 
size (> 3 cm vs. ≤ 3 cm) (detailed in Table 2). 
Prognostic significance of CD163+ TAMs in 
bladder cancer patients
4 of the 13 studies reported the correlation of 
CD163+ TAMs infiltration with RFS in bladder cancer 
patients who underwent TUR therapy. 3 of the 4 studies 
reported the patients received BCG therapy after TUR 
[16, 19, 23]. The pooled HR revealed that high density of 
Table 1: The characteristics of included studies
Study, Year Country Cases number
Tumor 
stages Therapy Biomarkers Antibody Source
Sample 
locations
Follow up
(midian months) Outcome
NOS 
score
Hanada T, 2000 Japan 63 Ta,T1-4 TUR,RC CD68 Anti-CD68,mAb,Dako,Glostrup, 
Denmark
W 65(3–153) OS 7
Koga F, 2004 Japan 69 T1,T2-4 RC CD68 Anti-
CD68,mAb,KP1,Dako,Carpenteria, 
California,dilution 1:200
I*,M 58(2–196) DSS 7
Takayama H, 
2009
Japan 44 Tis BCG CD68 Anti-CD68,mAb,DACO JAPAN, 
Kyoto, Japan
I,S,W 55.2(3–240.5 RFS 9
Ayari C, 2009 Canada 46 Ta,T1,Tis TUR+BCG CD68 Anti-
CD68,CloneKP1,DAKO,Glostrup, 
Denmark
W 26 RFS 8
Ajili F, 2013 Tunisia 27 Ta,T1 TUR+BCG CD68 Anti-CD68,CloneNCL-L-CD68, 
Leica,dilution 1:40
W 26 RFS 5
Suriano F, 2013 Italy 40 NMIBC TUR+BCG CD68, 
CD163
Anti-CD68,mAb,PG-M1;Anti-
CD163,mAb; dilution 1:200
W NR RFS 6
Ayari C, 2013 Canada 93 Ta,T1 TUR CD68 Anti-CD68,cloneKP1 from DAKO, 
Glostrup,Denmark,dilution 1:400
W 68.4 RFS 8
Sjödahl G, 2014 Sweden 52 MIBC RC CD68 Anti-CD68,cloneEBM11 from 
Dako,dilution1:1500
W 70 DSS,PFS 8
Lima L, 2014 Portugal 99 Ta,T1 TUR+BCG CD163 Anti-
CD163,mAb,Clone10D6;Novocastra-
Leica,dilution 1:100
S 97(13–163) RFS 8
Wang B, 2015 China 302 Ta,T1-4 TUR,RC CD68 Anti-CD68,DakoA/S,Glostrup,Copen
hagen,Denmark,dilution1:500
I,S 82(4–137) OS,RFS 8
Shao J, 2015 China 337 T1 TUR+THP CD163 Anti-163,10D6,Maixin,Fuzhou,China I,S 32.4(2.4–111.6) RFS 7
Boström MM, 
2015
Finland 184 Ta,Tis,T1-4 TUR,RC CD68 Anti-68,mAb,ab845, Abcam, 
U.K,dilution 1:5
W 6.9 (TUR);4.2 
(RC)
OS,RFS, 
DSS,PFS
9
Pichler R, 2016 Austria 40 Ta,T1,Tis TUR+BCG CD68, 
CD163
Anti-163,mAb,CloneMRQ-
26,prediluted,Roche;Anti-
68,mAb,ClonePG-M1,Dako,dilution 
1:50
W 29.5 RFS 8
Abbreviations: TUR: transurethral resection; RC: radical cystectomy; BCG: Bacillus Calmette Guerin vaccine; THP: Therarubicin; S: Stroma; I: Intratumoral 
or Islet; I*: invasive front; M: middle to superficial carcinoma parts; W: whole sample area (or not specified); OS: overall survival; RFS: relapse free survival; 
CSS: cancer specific survival.
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TAMs was correlated with worse RFS (HR = 1.54, 95% 
CI = 1.16 ~ 1.92) (Figure 4, Overall), without significant 
heterogeneity among studies (P = 0.115, I2 = 46.1%). 
Subgroup analysis according to the history of BCG 
therapy indicated that high density of CD163+ TAMs 
infiltration correlated with worse RFS in patients who 
underwent BCG therapy after TUR (HR = 2.44, 95% CI 
= 1.60 ~ 3.27) (Figure 4, with BCG therapy). Subgroup 
analysis according to the sample locations suggested that 
elevated CD163+ TAMs density in both total tumor and 
tumor stroma correlated with unfavourable RFS (HRs = 
2.44, 95% CI = 1.50 ~ 3.39, and = 2.08, 95% CI = 1.13 ~ 
3.02, respectively) (Supplementary Figure 2).
Publication bias
To evaluate the publication bias of the included 
studies, Begg’s and Egger’s tests were performed. Begg’s 
funnel plots showed no significant asymmetry among the 
included studies concerning the prognostic role of CD68+ 
TAMs with OS (p = 0.734) (Figure 5A), DSS (P = 1.0) 
(Figure 5B), and RFS (P = 0.119) (Figure 5C). As for the 
studies involved with the prognostic value of CD163+ 
TAMs with RFS, no significant publication bias was 
found by Begg’s funnel plots (P = 0.221) (Figure 5D). 
The results derived from Egger’s test were also consistent 
with abovementioned results (Supplementary Figure 3). 
Moreover, the results from “ trim and fill ” analyses also 
confirm our conclusions (detailed in Supplementary 
Figure 4) which suggest that potential missing data will 
not change the conclusion.
DISCUSSION 
Bladder cancer management is a thorny clinical 
problem because of frequent recurrence. TUR is 
performed as the primary treatment for NMIBC. 
However, most patients need to receive TUR 
repeatedly due to relapse. In order to reduce the rate of 
recurrence, BCG intravesical instillation as a type of 
immunotherapy was strongly recommended for patients 
diagnosed with carcinoma in situ (CIS), intermediate 
or high-risk NMIBC following TUR therapy. Recently, 
many studies have focused on other immunotherapy 
reagents. For example, Atezolizumab (Tecentriq™, 
MPDL3280A) as PD-L1/PD-1 immune checkpoint 
Figure 1: Flow diagram for the selection of included studies.
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inhibitor, was approved as a second-line therapy for 
advanced bladder cancer in 2016 [23, 24]. Accumulating 
evidences have suggested that immune cells play 
prominent function in tumor microenvironment of 
bladder cancer and have great potential for bladder 
cancer management [6, 23].
In this meta-analysis, 11 out of the 13 included 
studies analyzed the role of TAMs in bladder cancer with 
CD68 marker, in combination with or without CD163 
marker. 4 studies identified the TAMs with CD163 
biomarker, of which 1 study evaluated the TAMs in the 
tumor stroma and islet with CD163 alone. we systemically 
Figure 2: Forest plots evaluating the prognostic role of CD68+ TAMs in bladder cancer patients. (A) CD68+ TAMs with 
OS; (B) CD68+ TAMs with DSS; (C) CD68+  TAMs with PFS.
Table 2: The evaluation of elevated CD68+ macrophages with clinicopathological characteristics
Patient charateristics References of studies
Number of 
patients
Effect
models OR (95% CI)
Heterogeneity
I2 (%) Ph
Sex 
(Male vs. Female) 
11, 14, 17 202 fixed 0.47 (–0.10–1.039) 0 0.91
Age  
(≥ 70 years VS < 70 years)
14, 17 139 fixed 0.76 (–0.07–1.59) 1 0.315
carcinoma in situ 
(yes vs. no) 
14, 15 73 fixed 1.74 (–3.31–6.79) 0 0.50
Tumor stage 
(T1 vs. Ta)
14, 15, 17 166 fixed 2.77 (–0.72–6.26) 0 0.885
Number of tumor
(> 1 vs. 1)
14, 15, 17 166 fixed 1.24 (0.11–2.37) 0 0.90
Tumor grade 
(≥ 2 vs. 1)
11, 14, 17 202 fixed 1.90 (–0.38–4.18) 0 0.91
Tumor size 
(> 3 cm vs. ≤ 3 cm)
14, 15 73 fixed 1.17 (–0.51–2.86) 0 0.39
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Figure 3: Forest plot evaluating the prognostic role of CD68+ TAMs on RFS in bladder cancer patients. Subgroup 
analyses with regard to different sample locations.
Figure 4: Forest plot of pooled HR for CD163+ TAMs on RFS in bladder cancer patients. Subgroup analyses with regard to 
the history of BCG therapy.
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reviewed and analyzed the prognostic value of TAMs 
identified by CD68 or CD163 biomarker in bladder 
cancer patients. Some of these studies suggested that 
TAM infiltration was significantly associated with poor 
survival in bladder cancer patients [10, 14, 15]. However, 
the pooled results derived from our meta-analysis showed 
no significant correlation between the density of CD68+ 
TAMs and OS, RFS, DSS and PFS in bladder cancer 
patients. Furthermore, subgroup analyses also indicated 
no significant association between elevated CD68+ TAMs 
density and RFS in bladder cancer patients, regardless 
of the CD68+ identified in whole sample area (or not 
specified), tumor stroma or tumor islet. However, our 
results indicated that elevated CD163+ TAMs density could 
predict poor RFS in the bladder cancer patients after TUR 
therapy. Subgroup analysis was performed with regard 
to the instillation drugs used after TUR, and the pooled 
results indicated that the high CD163+ TAMs density was 
associated with poor RFS in the bladder cancer patients 
treated with TUR followed by BCG instillation. Moreover, 
subgroup analyses also suggested elevated CD163+ TAMs 
density predicted poor RFS regardless of the CD163+ 
TAMs identified in various sample locations.
Traditionally, macrophages play the defensive 
roles against foreign pathogens and contribute to 
phagocytosis and presentation of antigens expressed on 
the surface of the apoptotic or infected cells [25, 26]. In 
the past two decades, emerging studies have indicated 
that macrophages can be educated in different stages 
of TME, and TAMs can play multifaceted function 
in immune surveillance and tumor development that 
correlated with specific expression of markers (immune 
phenotypes). In majority of previous studies, CD68 was 
used as a common biomarker for all macrophages in 
tumor samples. However, macrophages can polarize into 
different phenotypes,  which are tightly regulated by 
tissue and tumor microenvironment [27, 28]. The most 
simplified classification of macrophages polarization 
were type 1 or inflammatory macrophages (M1) and 
type 2 or alternatively activated macrophages (M2) [29–
31]. The general belief is that M1 macrophages induce 
inflammation that may contribute to tumor initiation. 
In contrast, M2 macrophages mediate tissue repair and 
immunosuppression that contribute to tumor progression 
[6, 32]. In most cases, M1 macrophages were characterized 
by expression of CD80, CD86, human leukocyte antigen 
(HLA)-DR, inducible nitric oxide synthase (iNOS), while 
M2 macrophages generally express markers such as 
CD163, CD204, CD206 and Arginase 1 [31, 32]. Future 
studies using these macrophage polarization markers may 
further characterize subpopulation of macrophages that 
associate with bladder cancer prognosis. 
Figure 5: Begg’s funnel plot evaluating the potential publication bias among the included studies. (A). CD68 expression 
with RFS (P = 0.119); (B).CD68 expression with DSS (P = 1.0); (C). CD68 expression with OS (P = 0.734); (D). CD163 expression with 
RFS (P = 0.221).
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Current study is the first systemic review and 
meta-analysis to evaluate the prognostic value of CD68+ 
and CD163+ TAMs in bladder cancer. However, there 
are some limitations in our study. Firstly, heterogeneity 
among included studies cannot be completely avoided. 
Moreover, all the included studies were limited in English 
and Chinese language. Additionally, HRs and 95% 
CIs derived from multivariate analysis were generally 
extracted for this meta-analysis, however, Pichler’s study 
only provided univariate HRs and 95% CIs [22], and 
the HRs and 95% CIs were extracted from the Kaplan–
Meier survival curve in Suriano’s study [15], which may 
overstate the prognostic role of TAMs in bladder cancer 
patients. Finally, the included studies and patients numbers 
were relatively limited. Therefore, future large scale 
studies may be required to validate that conclusion from 
our study.
In summary, current systemic review and meta-
analysis draw a conclusion about the prognostic role of 
TAMs in bladder cancer patients. Our results suggested 
the elevated density of CD163+ TAMs predicted poor RFS 
in bladder cancer patients. While TAMs only identified 
with CD68 marker in bladder cancer samples were not 
significantly correlated with the prognostic outcomes and 
clinicopathological parameters in bladder patients. Due 
to the limitations in our study, further studies with larger 
sample size and rational design are still needed to validate 
our conclusion.
MATERIALS AND METHODS
Literature search strategy for relevant studies
This systemic review and meta-analysis was 
performed according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses statement 
(PRISMA) [33]. Related publications were retrieved 
from the database of Web of Science, Pubmed, Embase, 
Wanfang and China National Knowledge Infrastructure 
(CNKI). All the publications were searched by August 
8, 2017 with the following keywords: “macrophage” and 
“bladder cancer” or “bladder carcinoma”. The references 
from retrieved articles were also manually assessed to 
avoid the omission.
Studies selection
After removing duplications by Endnote X7, 
the remaining studies were reviewed by two authors 
independently, and disagreements were resolved by 
discussion and consensus. The inclusion criteria were 
as listed below:  studies focusing on the prognostic 
value of TAMs infiltration in bladder cancer;  TAMs 
were identified by immumohistochemical (IHC) staining 
in the bladder cancer samples;  with sufficient data to 
extract hazard ratios (HRs) and 95% confidence intervals 
(CIs). The exclusion criteria for the studies were in the 
following:  duplicated studies;  animal studies, case 
reports, comments, reviews and meeting abstracts;  
studies not relevant with prognostic analyses;  studies 
without sufficient data to extract HRs and 95% CIs.
Evaluation of the publications quality and data 
extraction
We evaluated the methodological quality of the 
included studies with the selection and outcome categories 
in the Newcastle-Ottawa Scale (NOS) system [34]. The 
evaluation was performed by two authors independently, 
and the disagreements were addressed by the discussion 
and consensus. After reviewing the full text of the included 
studies, we extracted the data with a predefined form 
including the following items: publication year, surname 
of the first author, country, cases number, tumor stages, 
therapy, and markers for macrophages, antibody source, 
sample locations, follow-up data and outcomes described 
in the studies. For the studies only with Kaplan-Meier 
survival curves, we extracted HRs and 95% CIs from the 
survival curves according to the methodology described 
by Tierney JF, et al [35] and via the Engauge Digitizer 4.1 
software.
Statistical analysis
Raw HRs and 95% CIs were extracted from all the 
included studies, then analysed with specified command 
provided by the Stata version 12.0 (Stata Corporation, 
Texas, USA), and the pooled results were presented with 
forest plots [36]. Heterogeneity of the included studies was 
described with Chi-squared and p value. I-square (I2) index 
was tested to evaluate the degree of total variation among 
the studies. I2 > 50% or p < 0.10 was defined as significant 
heterogeneous, and we preferred to choose random-
effects model for analyses in this situation. Otherwise, we 
performed the meta-analysis using the fixed-effects model. 
The pooled results were considered significant if the 95% 
CIs did not include 1. If HRs were provided with results 
derived from both univariate and multivariate analyses in 
the same study, multivariate models were preferred for 
increased accuracy. In order to evaluate the influence of 
potential missing data, we further performed “ trim and 
fill ” analysis [37]. Begg’s and Egger’s tests were also 
performed to evaluate the publication bias among the 
included studies [38, 39]. 
Abbreviations
TAMs, Tumor associated macrophages; IHC, 
immunohistochemistry; TME, tumor microenviroment; 
NMIBC, non-muscle invasive bladder cancer; MIBC, 
muscle invasive bladder cancer; BCG, Bacillus Calmette 
Guerin; TUR, transurethral resection of bladder tumor; 
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RC, radical cystectomy; CD68+, CD68 positive; CD163+, 
CD163 positive; OS, overall survival; RFS, relapse-free 
survival; PFS, progression-free survival; CSS, cancer-
specific survival; DSS, disease-specific survival; NOS, 
Newcastle-Ottawa Scale; HR, hazard ratio; OR, odds 
ratio; 95% CI, 95% confidence interval.
ACKNOWLEDGMENTS AND FUNDING 
Shuiqng Wu is sponsored by China Scholarship 
Council (#201606370183). Bin-Zhi Qian is funded 
by CRUK Career Development Fellowship C49791/
A17367 and ERC Starting Grant 716379. This work was 
undertaken in the MRC Centre for Reproductive Health 
which is funded by the MRC Centre grant MR/N022556/1.
The funder had no role in study design, data 
collection and analysis, decision to publish, or preparation 
of the manuscript.
CONFLICTS OF INTEREST
The authors declared no conflicts of interest.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA 
Cancer J Clin. 2016; 66:7–30.  
2. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, 
Malmström PU, Choi W. GUOCC, Lotan Y, Kassouf, W. 
Bladder cancer. Lancet. 2016; 6736:1–15. 
3. Breyer J, Burger M, Otto W. Immunotherapy in urothelial 
carcinoma: fade or future standard? Transl Androl Urol. 
2016; 5:662–67. 
4. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin 
versus mitomycin C in superficial bladder cancer: formal 
meta-analysis of comparative studies on tumor progression. 
Urology. 2004; 63:682–6. 
5. Douglass L, Schoenberg M. The Future of Intravesical Drug 
Delivery for Non-Muscle Invasive Bladder Cancer. Bladder 
Cancer. 2016; 2:285–92. 
6. Ruffell B, Coussens LM. Macrophages and therapeutic 
resistance in cancer. Cancer Cell. 2015; 27:462–72.
7. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang 
XZ, Zhao YW, Wei YQ. Prognostic significance of tumor-
associated macrophages in solid tumor: a meta-analysis of 
the literature. PLoS One. 2012; 7:e50946.
8. Mei J, Xiao Z, Guo C, Pu Q, Ma L, Liu C, Lin F, Liao 
H, You Z, Liu L. Prognostic impact of tumor-associated 
macrophage infiltration in non-small cell lung cancer: 
A systemic review and meta-analysis. Oncotarget. 2016; 
7:34217–28. https://doi.org/10.18632/oncotarget.9079.
9. Wu P, Wu D, Zhao L, Huang L, Chen G, Shen G, Huang J, Chai 
Y. Inverse role of distinct subsets and distribution of macrophage 
in lung cancer prognosis: a meta-analysis. Oncotarget. 2016; 
7:40451–60. https://doi.org/10.18632/oncotarget.9625.
10. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, 
Nomura Y. Prognostic value of tumor-associated macrophage 
count in human bladder cancer. Int J Urol. 2000; 7:263–69.
11. Koga F, Kageyama Y, Kawakami S, Fujii Y, Hyochi N, 
Ando N, Takizawa T, Saito K, Iwai A, Masuda H, Kihara K. 
Prognostic significance of endothelial Per-Arnt-sim domain 
protein 1/hypoxia-inducible factor-2α expression in a subset 
of tumor associated macrophages in invasive bladder cancer. 
J Urol. 2004; 171:1080–84.
12. Takayama H, Nishimura K, Tsujimura A, Nakai Y, 
Nakayama M, Aozasa K, Okuyama A, Nonomura N. 
Increased infiltration of tumor associated macrophages is 
associated with poor prognosis of bladder carcinoma in situ 
after intravesical bacillus Calmette-Guerin instillation. J 
Urol. 2009; 181:1894–900.
13. Ayari C, LaRue H, Hovington H, Decobert M, Harel 
F, Bergeron A, Têtu B, Lacombe L, Fradet Y. Bladder 
Tumor Infiltrating Mature Dendritic Cells and Macrophages 
as Predictors of Response to Bacillus Calmette-
Guérinimmunotherapy. Eur Urol. 2009; 55:1386–96.
14. Ajili F, Kourda N, Darouiche A, Chebil M, Boubaker S. 
Prognostic Value of Tumor-associated Macrophages Count 
in Human Non-muscle- invasive Bladder Cancer Treated 
by BCG Immunotherapy Prognostic Value of Tumor-
associated Macrophages Count in Human Non-muscle-
invasive Bladder Cancer Treated by BCG Immunotherapy. 
Ultrastruct Pathol. 2013; 37:56–61.
15. Suriano F, Santini D, Perrone G, Amato M, Vincenzi B, 
Tonini G, Muda A, Boggia S, Buscarini M, Pantano F. Tumor 
associated macrophages polarization dictates the efficacy of 
BCG instillation in non-muscle invasive urothelial bladder 
cancer. J Exp Clin Cancer Res. 2013; 32:87. 
16. Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Têtu 
B, Fradet V, Fradet Y. High level of mature tumor-infiltrating 
dendritic cells predicts progression to muscle invasion in 
bladder cancer. Hum Pathol. 2013; 44:1630–37. 
17. Sjödahl G, Lövgren K, Lauss M, Chebil G, Patschan O, 
Gudjonsson S, Månsson W, Fernö M, Leandersson K, 
Lindgren D, Liedberg F, Höglund M. Infiltration of CD3 
and CD68 cells in bladder cancer is subtype specific and 
affects the outcome of patients with muscle-invasive 
tumors. Urol Oncol. 2014; 32:791–97.
18. Lima L, Oliveira D, Tavares A, Amaro T, Cruz R, Oliveira 
MJ, Ferreira JA, Santos L. The predominance of M2-
polarized macrophages in the stroma of low-hypoxic 
bladder tumors is associated with BCG immunotherapy 
failure. Urol Oncol. 2014; 32:449–57.
19. Wang B, Liu H, Dong X, Wu S, Zeng H, Liu Z, Wan D, 
Dong W, He W, Chen X, Zheng L, Huang J, Lin T. High 
CD204 + tumor-infiltrating macrophage density predicts a 
poor prognosis in patients with urothelial cell carcinoma 
of the bladder. Oncotarget. 2015; 6:20204–14. https://doi.
org/10.18632/oncotarget.3887.
20. Shao J, Zhou H, Zhou Z, Hu Q, Hou J, Zhuo X. The 
value of tumor associated macrophages in tumorstroma in 
Oncotarget25303www.oncotarget.com
predicting initial recurrence of patients with non-muscle-
invasive bladder transitional cell cancer. Chin J Exp Surg. 
2015; 32:1175–78.
21. Boström MM, Irjala H, Mirtti T, Taimen P, Kauko T, Ålgars 
A, Jalkanen S, Boström PJ. Tumor-Associated Macrophages 
Provide Significant Prognostic Information in Urothelial 
Bladder Cancer. PLoS One. 2015; 10:e0133552.
22. Pichler R, Fritz J, Zavadil C, Schäfer G, Culig Z, Brunner 
A. Tumor-infiltrating immune cell subpopulations influence 
the oncologic outcome after intravesical Bacillus Calmette-
Guérin therapy in bladder cancer. Oncotarget. 2016; 
7:39916–30. https://doi.org/10.18632/oncotarget.9537.
23. Kim J, and Investigative and Clinical Urology. Immune 
checkpoint blockade therapy for bladder cancer treatment. 
Investig Clin Urol. 2016; 57:S98–105.
24. Inman BA, Longo TA, Ramalingam S, Harrison MR. 
Atezolizumab: a PD-L1  blocking antibody for bladder 
cancer. Clin Cancer Res. 2017; 23:1886–1890.
25. Rhee I. Diverse macrophages polarization in tumor 
microenvironment. Arch Pharm Res. 2016; 39:1588–96.
26. Hill AA, Reid Bolus W, Hasty AH. A decade of progress 
in adipose tissue macrophage biology. Immunol Rev. 2014; 
262:134–152.
27. Cassetta L, Cassol E, Poli G. Macrophage polarization in 
health and disease. Sci World J. 2011; 11:2391–2402.
28. Ohlsson SM, Linge CP, Gullstrand B, Lood C, Johansson 
A, Ohlsson S, Lundqvist  A, Bengtsson AA, Carlsson 
F, Hellmark T. Serum from patients with systemic 
vasculitis induces alternatively activated macrophage M2c 
polarization. Clin Immunol. 2014; 152:10–19.
29. Mosser DM, Edwards JP. Exploring the full spectrum of 
macrophage activation. Nat Rev Immunol. 2008; 8:958–69.
30. Nardin A, Abastado JP. Macrophages and cancer. Front 
Biosci. 2008; 13:3494–505. 
31. Takeya M, Komohara Y. Role of tumor-associated 
macrophages in human malignancies: friend or foe? Pathol 
Int. 2016; 66:491–505. 
32. Martinez FO, Helming L, Gordon S. Alternative Activation 
of Macrophages: An Immunologic Functional Perspective. 
Annu Rev Immunol. 2009; 27:451–83. 
33. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche 
PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, 
Moher D. The PRISMA statement for reporting systematic 
reviews and meta-analyses of studies that evaluate health 
care interventions: explanation and elaboration. J Clin 
Epidemiol. 2009; 62:e1–34.
34. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, 
Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) 
for assessing the quality of nonrandomised studies in meta-
analyses. Available from: http://www.ohri.ca/programs/
clinical_epidemiology/oxford.asp.
35. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. 
Practical methods for incorporating summary time-to-event 
data into meta-analysis. Trials. 2007; 8:16.
36. Chaimani A, Mavridis D, Salanti G. A hands-on practical 
tutorial on performing meta-analysis with Stata. Evid Based 
Ment Health. 2014; 17:111–6. 
37. Duval S, Tweedie R. Trim and Fill: A Simple Funnel-Plot-
Based Method of Testing and Adjusting for Publication Bias 
in Meta-Analysis. Biometrics. 2000; 56:455–63.https://doi.
org/10.1111/j.0006-341X.2000.00455.x.
38. Begg CB, Mazumdar M. Operating Characteristics of a 
Rank Correlation Test for Publication Bias. Biometrics. 
1994; 50:1088–101.
39. Egger M, Davey Smith G, Schneider M, Minder C. Bias 
in meta-analysis detected by a simple, graphical test. BMJ. 
1997; 315:629–34.
